In this review
Three prices cover different purchases
The weight-care page separates branded care from compounded products. Its branded starting figure is $149 per month for consultation, with medicine obtained through a separate pharmacy pathway. Do not put that figure beside a medication-included price and call it the cheaper drug plan. [1]
Compounded semaglutide starts at $199, and tirzepatide with B12 at $249. Those pages list the provider visit, shipping and supplies as included. They offer thirty- and ninety-day supply choices, but selecting ninety days on semaglutide leaves the starting-price headline unchanged. The complete selected quote and actual supplied count still need confirmation. [2] [3]
Compare consultation and medication on the same basis in the GLP-1 total-cost planner.
A refill request is a practical distinction
The product pages say no auto-subscribe. The help centre says patients request refills through the account and the provider reviews progress before approving more. That can suit someone who prefers a deliberate next purchase; it does not guarantee a refill, an unchanged price or an immediate reply. [2] [3] [4]
Labs are described as optional for these compounded plans, subject to provider judgment. Confirm any required tests and collection charges. Provider messaging and progress review do not establish scheduled dietitian appointments or a complete nutrition programme. An additional laboratory service or a coming-soon medication stack should not be counted as an included benefit. [1] [4]
Compare an appointment-led service in our Form Health continuing-care review.
The cancellation cutoff arrives before the charge
The FAQ says medication is billed when shipped and that processing starts as soon as an order is placed. Once processing starts, it says an order cannot be changed or canceled. Pay-only-if-treatment-is-appropriate wording does not make an already processed request freely withdrawable. [4]
The older refund page instead mentions pre-shipment subscription changes and finality after payment and carrier handoff. Ask which terms apply to the current selected purchase. Dispensed medicine cannot be returned, and the thirty-day unopened-goods policy covers over-the-counter products. A transit-loss reshipment provision is not a refund promise for intolerance or disappointment. [5]
Compare another early order commitment in the Näky commitment review.
Compare another clinical-review and purchase arrangement in our Sunlight care-and-order review.
Keep the preparation separate from the brand
The semaglutide page permits patient-specific additives such as B12; tirzepatide explicitly names B12. Those descriptions do not provide the complete concentration, quantity or patient-specific rationale. They do not establish that a vitamin addition improves the outcome or makes the preparation equivalent to a branded product. [2] [3]
Compounded drugs are not FDA-approved, and post-shortage compounding remains subject to patient-specific conditions. Clinical appropriateness and actual pharmacy details must be settled for the prescription. I would compare KIN on the complete quote and usable continuing care, keeping generic marketing and branded trial results out of claims about the supplied compound. [6] [7] [8]
Read a specific treatment-outcome question in the GLP-1 lean-mass evidence.
Understanding the cost
Compounded semaglutide starts at $199; tirzepatide+B12 starts at $249, with shipping, supplies and visit listed included. Branded care starts at $149/month for consultation, with medication separately obtained. Confirm full selected supply and drug costs; no universal all-dose or 90-day price established.
Build your cost estimateSources
- KIN Meds: separate branded consultation and compounded weight-care paths
- KIN Meds: compounded semaglutide and selected 90-day supply
- KIN Meds: compounded tirzepatide with B12
- KIN Meds: expanded payment, cancellation, refill, shipping and pharmacy answers
- KIN Meds: full returns/refund policy and prescription exclusions
- KIN Meds: independent clinical services and pharmacy-choice terms
- FDA: compounded drugs and premarket approval limits
- FDA: patient-specific GLP-1 compounding conditions after shortage resolution
This review evaluates public service information. It does not claim patient enrollment, product testing or measurement of clinical outcomes.